Copyright 1999 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
I am writing in response to Dr Campbell's question regarding the monitoring of our patient during her hospital stay.1 We did in fact monitor both renal and hepatic functions. We kept laboratory monitoring to a minimum, as she was severly anemic on admission. We evaluated hepatic functions at the beginning of treatment and at the end of her third treatment course. We followed her serum chemistry studies and renal functions closely to help us aggressively manage fluid and electrolyte abnormalities. Fortunately for our patient, no abnormalities were noted and her hospital course was uneventful.
Gordon RA. Treatment of Acute Lead Encephalopathy—Reply. Arch Pediatr Adolesc Med. 1999;153(11):1202. doi: